PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Guidelines - Inflammatory bowel disease

PAD Profile : Guidelines - Inflammatory bowel disease

Keywords :
IBD, CD, Chronic Bowel Disorder, inflammatory bowel disease, corticosteroid, 5-ASA, aminosalicylate, UC, ulcerative Colitis, prednisolone, mesalazine, crohns, lower GI symptoms, Crohn's, Crohn's disease

Traffic Light Status

Status 1 of 2.

Status :
N/A
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
N/A
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
01 March 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

06 November 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommend the use of an online toolkit to support prescribers when a patient presents with symptoms of IBD. The toolkit has been developed by the Royal College of Practitioners (RCGP) and Crohn's & Colitis UK. Follow this link to the toolkit  https://www.rcgp.org.uk/ibd

Associated BNF Codes

01. Gastro-Intestinal System
01.05.01. Aminosalicylates
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More